Generics give injectables a shot


Vial and syringe

Sterile injectables are difficult to manufacture well, but the market is growing © Shutterstock

Generics companies are scrabbling for footholds in the world of sterile injectable products. A rash of deals has seen India’s Lupin Pharmaceuticals and Aurobindo, as well as US firms Par Pharmaceuticals and Mylan, go for bigger slices of the multi-billion pound market.

On 3 February, Lupin agreed to buy Nanomi, an injectables specialist based in the Netherlands, for an undisclosed amount. In January, Aurobindo finalised a deal with Actavis to take over chunks of its European operations, including a platform to launch injectable products based on Actavis’s hospital sales infrastructure.

In the US, Par Pharmaceuticals’ $490 million (£300 million) buyout of injectables expert JHP Pharmaceuticals follows on from a string of similar deals last year, notably Mylan’s takeover of Agila injectables, worth up to $1.75 billion, bolstering Mylan’s position as a major injectables producer.

Injectables is an attractive growing market, linked to growth in complex biological drugs – particularly as generic biosimilar versions start to be approved. Most of these products are unsuitable for formulating as tablets, so need to be injected. Diabetes and cancer treatments are also commonly injected, and with ageing populations demand for these medicines is increasing steadily.

But manufacturing injectables is a tricky business, as shown by a steady stream of quality concerns, failed manufacturing inspections and ensuing product shortages. That means the barriers to entry are high – hence new players are buying their way in through acquisitions rather than starting from scratch.


Related Content

Hospira buyout is a shot in the arm for Pfizer’s biosimilars

12 February 2015 Business

news image

$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new de...

Allergan steps away from generics with sale to Teva

29 July 2015 Business

news image

$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top...

Most Read

Agatha Christie, the queen of crime chemistry

28 August 2015 Feature

news image

Kathryn Harkup looks at how Agatha Christie used her chemical training in her detective novels

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

A risky business

28 August 2015 In the Pipeline

news image

Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe

Exploiting the data mine

13 August 2015 Feature

news image

Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, repor...